AR036175A1 - Derivados de la dolastatina 10, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos en la preparacion de medicamentos, procesos para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de dichos compuestos - Google Patents
Derivados de la dolastatina 10, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos en la preparacion de medicamentos, procesos para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de dichos compuestosInfo
- Publication number
- AR036175A1 AR036175A1 ARP020102678A ARP020102678A AR036175A1 AR 036175 A1 AR036175 A1 AR 036175A1 AR P020102678 A ARP020102678 A AR P020102678A AR P020102678 A ARP020102678 A AR P020102678A AR 036175 A1 AR036175 A1 AR 036175A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- dioxolyl
- alkoxy
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Derivados de la dolastatina 10 de la fórmula (1), en donde R1, R2 y R3 son cada uno independientemente hidrógeno ó alquilo C1-4; R4 es hidrógeno; alquilo sustituido opcionalmente con uno a tres sustituyentes seleccionados del grupo consistente en hidroxilo, alcoxilo, amino, mono- o dialquilamino, carboxilo, alcoxicarbonilo, carbamoiloxilo, alquilcarboniloxilo, carbamoilo o halógeno; alquenilo; alquinilo; cicloalquilo C3-7; arilo sustituido opcionalmente con uno a tres sustituyentes seleccionados del grupo consistente en halógeno, alcoxicarbonilo, carbamoilo, sulfamoilo, alquilcarboniloxilo, ciano, mono- o dialquilamino, alquilo, alcoxilo, fenilo, fenoxilo, trifluorometilo, trifluorometoxilo, tioalquilo, hidroxilo, alquilcarbonilamino, heterociclilo, 1,3-dioxolilo, 1,4-dioxolilo, amino o bencilo; aralquilo con el grupo arilo sustituido opcionalmente con uno a tres sustituyentes seleccionados del grupo consistente en halógeno, alcoxicarbonilo, sulfamoilo, alquilcarboniloxilo, ciano, mono- o dialquilamino, alquilo, alcoxilo, fenilo, fenoxilo, trifluorometilo, trifluorometoxilo, tioalquilo, hidroxilo, alquilcarbonilamino, heterociclilo, 1,3-dioxolilo, 1,4-dioxolilo, amino o bencilo; o heterociclilalquilo; R5 es alquil C1-6-amino; hidroxilo; cicloalquil C3-7-amino sustituido opcionalmente por fenilo o bencilo; arilamino; aralquilamino con alquileno C1-4 y el grupo arilo sustituido opcionalmente con uno a tres sustituyentes seleccionados del grupo consistente en halógeno, alcoxicarbonilo, sulfamoilo, alquilcarboniloxilo, carbamoiloxilo, ciano, mono- o dialquilamino, alquilo, alcoxilo, fenilo, fenoxilo, trifluorometilo, trifluorometoxilo, tioalquilo, hidroxilo, alquilcarbonilamino, heterociclilo, 1,3-dioxolilo, 1,4-dioxolilo, amino o bencilo; alcoxilo C1-4; benzhidrazino; heterociclilo sustituido opcionalmente con uno a tres sustituyentes seleccionados del grupo consistente en bencilo, benzhidrilo, alquilo, hidroxilo, alcoxilo, alquilcarbamoiloxilo, amino, mono- o dialquilamino, acilamino, alcoxicarbonilamino, fenilo o halógeno; heterociclilamino; heterocicloalquilamino con el grupo heterociclilo sustituido opcionalmente con uno a tres sustituyentes seleccionados del grupo consistente en bencilo, benzhidrilo, alquilo, hidroxilo, alcoxilo, alquilcarbamoiloxilo, amino, dialquilamino, acilamino, alcoxicarbonilamino o halógeno; aralquiloxilo y aralquilo ambos sustituidos opcionalmente con uno a tres sustituyentes del grupo consistente en halógeno, alcoxicarbonilo, sulfamoilo, alquilcarboniloxilo, ciano, mono- o dialquilamino, alquilo, alcoxilo, fenilo, fenoxilo, trifluorometilo, trifluorometoxilo, tioalquilo, hidroxilo, alquilcarbonilamino, heterociclilo, 1,3-dioxolilo, 1,4-dioxolilo, amino, aminosulfonilo o bencilo; y n es un número entero de 0, 1 ó 2; y las sales farmacéuticamente aceptables de los mismos. Dichos compuestos tienen actividad antitumoral y son útiles para el tratamiento de enfermedades malignas, particularmente cáncer colorrectal, cáncer de pulmón, cáncer de mama, cáncer de estómago, cáncer cervical y cáncer de vejiga. Composiciones farmacéuticas que los comprenden, uso de dichos compuestos en la preparación de medicamentos, procesos para la preparación de dichos compuestos e intermediarios útiles en la preparación de dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01117410 | 2001-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036175A1 true AR036175A1 (es) | 2004-08-18 |
Family
ID=8178073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102678A AR036175A1 (es) | 2001-07-19 | 2002-07-17 | Derivados de la dolastatina 10, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos en la preparacion de medicamentos, procesos para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de dichos compuestos |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6737409B2 (es) |
| EP (1) | EP1412328B1 (es) |
| JP (1) | JP2004534859A (es) |
| KR (2) | KR20060057652A (es) |
| CN (1) | CN1553897A (es) |
| AR (1) | AR036175A1 (es) |
| AT (1) | ATE341537T1 (es) |
| BR (1) | BR0211289A (es) |
| CA (1) | CA2453987A1 (es) |
| CO (1) | CO5550462A2 (es) |
| DE (1) | DE60215179T2 (es) |
| DK (1) | DK1412328T3 (es) |
| ES (1) | ES2272763T3 (es) |
| GT (1) | GT200200154A (es) |
| HR (1) | HRP20040043A2 (es) |
| HU (1) | HUP0401253A2 (es) |
| IL (1) | IL159890A0 (es) |
| MX (1) | MXPA04000577A (es) |
| MY (1) | MY127718A (es) |
| NO (1) | NO20040198L (es) |
| NZ (1) | NZ530655A (es) |
| PA (1) | PA8551001A1 (es) |
| PE (1) | PE20030258A1 (es) |
| PL (1) | PL367682A1 (es) |
| PT (1) | PT1412328E (es) |
| RU (1) | RU2296750C2 (es) |
| SI (1) | SI1412328T1 (es) |
| UY (1) | UY27388A1 (es) |
| WO (1) | WO2003008378A1 (es) |
| ZA (1) | ZA200400334B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7064211B2 (en) | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| IL163868A0 (en) * | 2002-03-22 | 2005-12-18 | Eisai Co Ltd | Hermiasterlin derivatives and uses thereof |
| US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| US7312343B2 (en) * | 2004-06-02 | 2007-12-25 | Hoffmann-La Roche Inc. | Synthesis of α-amino-β-alkoxy-carboxylic acid esters |
| AU2005332660A1 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| MX2007006746A (es) * | 2004-12-13 | 2007-07-09 | Hoffmann La Roche | Proceso novedoso para la manufactura de derivados del acido 3-pirrolidin-2-il-propionico. |
| JP2008523002A (ja) * | 2004-12-13 | 2008-07-03 | エフ．ホフマン−ラ ロシュ アーゲー | 少なくとも１つのドラスタチン１０誘導体を含有する新規な医薬組成物 |
| US20060189893A1 (en) * | 2005-01-06 | 2006-08-24 | Diamics, Inc. | Systems and methods for detecting abnormal cells |
| US20060161076A1 (en) * | 2005-01-06 | 2006-07-20 | Diamics, Inc. | Systems and methods for collection of cell clusters |
| MX2007008349A (es) * | 2005-01-13 | 2007-07-25 | Hoffmann La Roche | Nueva sintesis de una etapa de aminas disustituidas utiles. |
| EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
| WO2007008848A2 (en) * | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| WO2007008603A1 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| NZ572836A (en) | 2006-05-16 | 2011-12-22 | Pharmascience Inc | Iap bir domain binding compounds |
| US20080003652A1 (en) * | 2006-06-28 | 2008-01-03 | Hans Iding | Novel enzymatic process for the manufacture of Boc-Dap-Oh priority to related application(s) |
| CR20190516A (es) | 2007-07-16 | 2020-02-18 | Genentech Inc | ANTICUERPOS ANTI-CD79B E INMUNOCONJUGADOS (Divisional 2015-0040) |
| PE20090481A1 (es) | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
| CN101981055B (zh) | 2008-01-31 | 2016-03-09 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
| PL2842575T3 (pl) | 2008-03-18 | 2018-02-28 | Seattle Genetics, Inc. | Koniugaty aurystatyny lek łącznik |
| WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
| SG10201501095WA (en) | 2010-02-12 | 2015-04-29 | Pharmascience Inc | Iap bir domain binding compounds |
| ES2528956T3 (es) | 2010-06-10 | 2015-02-13 | Seattle Genetics, Inc. | Nuevos derivados de auristatina y su uso |
| CN103379912B (zh) | 2010-09-29 | 2016-03-16 | 西雅图基因公司 | 正羧烷基耳他汀及其应用 |
| ES2543888T3 (es) * | 2011-03-16 | 2015-08-25 | Seattle Genetics, Inc. | N-carboxialquil-auristatinas y su utilización |
| MX371526B (es) * | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
| BR112013030372A2 (pt) | 2011-05-27 | 2016-08-30 | Ambrx Inc | composições contendo, métodos envolvendo, e usos de derivados de dolastatin ligados ao aminoácido não natural |
| JP6089108B2 (ja) | 2012-09-20 | 2017-03-01 | セルトリオン， インク． | ドラスタチン１０誘導体、その製造方法およびそれを含む抗癌剤組成物 |
| WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
| PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| CN105949277B (zh) * | 2015-05-05 | 2019-03-01 | 成都永泰诺科技有限公司 | 一种抗肿瘤化合物及其用途 |
| US10792365B2 (en) * | 2016-03-29 | 2020-10-06 | Toray Industries, Inc. | Peptide derivative and use thereof |
| CN109021065B (zh) * | 2017-06-08 | 2021-10-01 | 复旦大学 | 一种制备海兔毒素Dolastatin10的方法 |
| AU2022338463A1 (en) | 2021-09-03 | 2024-03-21 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
-
2002
- 2002-07-15 US US10/195,698 patent/US6737409B2/en not_active Expired - Fee Related
- 2002-07-17 UY UY27388A patent/UY27388A1/es not_active Application Discontinuation
- 2002-07-17 AR ARP020102678A patent/AR036175A1/es not_active Application Discontinuation
- 2002-07-17 DK DK02764710T patent/DK1412328T3/da active
- 2002-07-17 HU HU0401253A patent/HUP0401253A2/hu unknown
- 2002-07-17 KR KR1020067008692A patent/KR20060057652A/ko not_active Application Discontinuation
- 2002-07-17 SI SI200230447T patent/SI1412328T1/sl unknown
- 2002-07-17 WO PCT/EP2002/007931 patent/WO2003008378A1/en active IP Right Grant
- 2002-07-17 NZ NZ530655A patent/NZ530655A/en unknown
- 2002-07-17 KR KR1020047000854A patent/KR100611540B1/ko not_active IP Right Cessation
- 2002-07-17 PT PT02764710T patent/PT1412328E/pt unknown
- 2002-07-17 MX MXPA04000577A patent/MXPA04000577A/es active IP Right Grant
- 2002-07-17 AT AT02764710T patent/ATE341537T1/de not_active IP Right Cessation
- 2002-07-17 PL PL02367682A patent/PL367682A1/xx not_active Application Discontinuation
- 2002-07-17 JP JP2003513938A patent/JP2004534859A/ja active Pending
- 2002-07-17 CN CNA028177622A patent/CN1553897A/zh active Pending
- 2002-07-17 RU RU2004105145/04A patent/RU2296750C2/ru not_active IP Right Cessation
- 2002-07-17 EP EP02764710A patent/EP1412328B1/en not_active Expired - Lifetime
- 2002-07-17 CA CA002453987A patent/CA2453987A1/en not_active Abandoned
- 2002-07-17 ES ES02764710T patent/ES2272763T3/es not_active Expired - Lifetime
- 2002-07-17 MY MYPI20022704A patent/MY127718A/en unknown
- 2002-07-17 IL IL15989002A patent/IL159890A0/xx unknown
- 2002-07-17 BR BR0211289-2A patent/BR0211289A/pt not_active IP Right Cessation
- 2002-07-17 DE DE60215179T patent/DE60215179T2/de not_active Expired - Fee Related
- 2002-07-18 PA PA20028551001A patent/PA8551001A1/es unknown
- 2002-07-18 GT GT200200154A patent/GT200200154A/es unknown
- 2002-07-19 PE PE2002000643A patent/PE20030258A1/es not_active Application Discontinuation
-
2004
- 2004-01-15 ZA ZA2004/00334A patent/ZA200400334B/en unknown
- 2004-01-16 NO NO20040198A patent/NO20040198L/no not_active Application Discontinuation
- 2004-01-19 HR HR20040043A patent/HRP20040043A2/hr not_active Application Discontinuation
- 2004-01-20 CO CO04003736A patent/CO5550462A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036175A1 (es) | Derivados de la dolastatina 10, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos en la preparacion de medicamentos, procesos para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de dichos compuestos | |
| CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| DE602004024375D1 (de) | Carboxamidderivate | |
| BRPI0515896A (pt) | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus | |
| HUP0400384A2 (hu) | Benzamidinszármazékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
| ATE452129T1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
| EA200501095A1 (ru) | Фенилацетамиды и их применение в качестве модуляторов глюкокиназы | |
| ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| ECSP066315A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| CL2004000965A1 (es) | Compuestos derivados de 2h-pirazol-3-il de formula definida, que actuan como inhibidores de quinasa p38 y tnf; composicion farmaceutica que comprende a uno de los compuestos; uso de la composicion en la preparacion de un medicamento; y uso de los com | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| TW200626553A (en) | Novel compounds | |
| HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
| SE0302192D0 (sv) | Novel compounds | |
| BRPI0508107A (pt) | derivados de indazol e composições farmacêuticas contendo os mesmos | |
| RU2008114048A (ru) | Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |